| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H13BrF2N2O4 |
| Molecular Weight | 415.186 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC(=O)NC1=CC=C(OC2=CC(F)=C(F)C=C2Br)C=C1)C(O)=O
InChI
InChIKey=BNYDDAAZMBUFRG-ZDUSSCGKSA-N
InChI=1S/C16H13BrF2N2O4/c17-10-5-11(18)12(19)6-14(10)25-9-3-1-8(2-4-9)21-15(22)7-13(20)16(23)24/h1-6,13H,7,20H2,(H,21,22)(H,23,24)/t13-/m0/s1
| Molecular Formula | C16H13BrF2N2O4 |
| Molecular Weight | 415.186 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
WAY-213613 to be a potent, EAAT2-preferring, competitive nonsubstrate inhibitor of EAAT2. WAY-213613 was devoid of either agonist or antagonist activity at the ionotropic NMDA and AMPA receptors expressed natively in cultured hippocampal neurons, or at the human mGlu receptors 1, 2, and 4 heterologously expressed in stable cell lines. It is used in scientific research into the function of the glutamate transporters.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 85.0 nM [IC50] | |||
| 5.0 µM [IC50] | |||
| 3.8 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Еhe effect of WAY-213613 on glutamateinduced
currents in oocytes was examined. Application of 30
uM WAY-213613 (or indeed the other three compounds described in this study) to EAAT2 injected oocytes failed to induce a transporter-like current, indicating the compound to be a nonsubstrate.
